OBJECTIVES: To evaluate varenicline's efficacy for smoking cessation versus bupropion SR and placebo and to explore whether factors typically predictive of abstinence influence varenicline's efficacy versus placebo, as measured by the week 9-12 continuous abstinence rate (CAR9-12). METHODS: Smokers in 2 randomized, placebo-controlled trials received varenicline 1 mg BID (n=696), bupropion SR 150 mg BID (n=671), or placebo (n=685) for 12 weeks. Nontreatment followup lasted 40 weeks. RESULTS: CAR(9-12) was greater for varenicline (44.0%) versus bupropion SR (29.7%; P<0.0001) and placebo (17.7%; P<0.0001). CAR(9-12) for varenicline versus placebo was not affected by age, gender, or nicotine dependence level. CONCLUSIONS:Varenicline was more efficacious than bupropion SR or placebo. Varenicline's efficacy versus placebo was not influenced by factors predictive of abstinence.
RCT Entities:
OBJECTIVES: To evaluate varenicline's efficacy for smoking cessation versus bupropion SR and placebo and to explore whether factors typically predictive of abstinence influence varenicline's efficacy versus placebo, as measured by the week 9-12 continuous abstinence rate (CAR9-12). METHODS: Smokers in 2 randomized, placebo-controlled trials received varenicline 1 mg BID (n=696), bupropion SR 150 mg BID (n=671), or placebo (n=685) for 12 weeks. Nontreatment followup lasted 40 weeks. RESULTS:CAR(9-12) was greater for varenicline (44.0%) versus bupropion SR (29.7%; P<0.0001) and placebo (17.7%; P<0.0001). CAR(9-12) for varenicline versus placebo was not affected by age, gender, or nicotine dependence level. CONCLUSIONS:Varenicline was more efficacious than bupropion SR or placebo. Varenicline's efficacy versus placebo was not influenced by factors predictive of abstinence.
Authors: Sherry A McKee; Andrea H Weinberger; Julia Shi; Jeanette Tetrault; Sabrina Coppola Journal: Nicotine Tob Res Date: 2012-04-06 Impact factor: 4.244
Authors: H Rollema; A Shrikhande; K M Ward; F D Tingley; J W Coe; B T O'Neill; E Tseng; E Q Wang; R J Mather; R S Hurst; K E Williams; M de Vries; T Cremers; S Bertrand; D Bertrand Journal: Br J Pharmacol Date: 2010-03-22 Impact factor: 8.739
Authors: Martin C Mahoney; Deborah O Erwin; Annamaria Masucci Twarozek; Frances G Saad-Harfouche; Elisa M Rodriguez; Xiaoxi Sun; Willie Underwood; Chester Fox Journal: Prev Med Date: 2018-06-25 Impact factor: 4.018
Authors: Julie C Gass; Jennifer M Wray; Larry W Hawk; Martin C Mahoney; Stephen T Tiffany Journal: Psychopharmacology (Berl) Date: 2012-04-04 Impact factor: 4.530
Authors: Hélène M Faessel; R Scott Obach; Hans Rollema; Patanjali Ravva; Kathryn E Williams; Aaron H Burstein Journal: Clin Pharmacokinet Date: 2010-12 Impact factor: 6.447
Authors: Paul M Cinciripini; Jason D Robinson; Maher Karam-Hage; Jennifer A Minnix; Cho Lam; Francesco Versace; Victoria L Brown; Jeffrey M Engelmann; David W Wetter Journal: JAMA Psychiatry Date: 2013-05 Impact factor: 21.596